Praxis Precision Medicines (PRAX) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
16 Nov, 2026Ulixacaltamide regulatory outlook
Jan. 29 PDUFA is the key near-term decision; management said confidence in approval was high after a late-cycle meeting it characterized as label-focused.
Remaining regulatory work includes agreeing on potential PMCs/PMRs and finalizing the label; manufacturing activities continued, with significant inventory and dual capacity for most of the process.
Broad adult essential tremor studies showed every subgroup nominally superior to placebo; management expects no meaningful label limits from study inclusion criteria or drug interactions.
Management expects scheduling may occur, but said Schedule IV, Schedule V or no scheduling would not change its launch approach; neurologists are the target prescribers.
Commercial strategy and long-term use
Initial treatment can cause dizziness and brain fog for some patients; management said these effects ease with continued use at 20 mg, making controlled patient experience central to launch execution.
Launch plans include significant resources and coverage across the prescribing base, aiming to build demand while managing patient experience; management estimated the opportunity at $36B.
Praxis Horizon is operational for end-to-end prescription workflows, linking EMR prescribing, prior-authorization data and prescription routing through a dedicated pharmacy channel.
Long-term follow-up showed continued improvement; the goal is ~200 patients with two years of follow-up, with additional data expected as follow-up completes.
Essential tremor treatment is chronic, and management said it intends to keep patients on therapy as long as possible because the condition progressively reduces function and has no cure.
Pipeline and upcoming milestones
The portfolio includes 21 programs and two NDAs; three ulixacaltamide extension studies in restless legs syndrome, Parkinson’s tremor and autism spectrum disorder were set to start soon.
Management expects data from several programs next year; two next-generation ulixacaltamide programs are in IND-enabling work, while an active-delivery patch is targeted to enter the clinic next year.
Relutrigine’s PDUFA for SCN2A/SCN8A developmental encephalopathies is expected in a little over a month; management said FDA discussions were less advanced than for ulixacaltamide.
Management cited 300,000 U.S. patients in the relevant population and a $5B-$8B peak total market opportunity for relutrigine.
EMERALD data in broader developmental and epileptic encephalopathies were targeted for year-end, subject to investigator closeout; the study has ~200 patients across many sites and countries.
Latest events from Praxis Precision Medicines
- Two near-term launches anchor a pipeline with >$20B in peak-sales guidance.PRAX
Investor Day 2026 - Ulixacaltamide nears a January decision as launches and pipeline programs advance.PRAX
3rd Annual Guggenheim Healthcare Innovation Conference - Two NDAs near FDA decisions as $1.3B in liquidity supports operations into 2028.PRAX
Q3 2026 - $1.4B cash, late-stage FDA reviews, and commercial readiness drive 2027 launch plans.PRAX
Q2 2026 - Four CNS therapies with blockbuster potential target >$20B peak sales by 2028.PRAX
Corporate presentation - Pivotal epilepsy studies and a robust pipeline set up multiple clinical catalysts through early 2026.PRAX
Jefferies Global Healthcare Conference 2025 - Accelerated clinical and regulatory strategies are driving earlier market entry for key therapies.PRAX
Fireside Chat - Two NDAs filed, strong clinical data, and $1.5B cash position support 2026 launches.PRAX
Q4 2025 - Q3 net loss was $51.9M; $411.2M cash funds late-stage CNS trials into 2027 with key data in 2025.PRAX
Q3 2024 - Multiple late-stage clinical readouts and $433.8M cash support operations into 2027.PRAX
Q2 2024